Search for content, post, videos

First patient enrolled in Ultimovacs’ DOVACC trial

Ultimovacs lab
Ultimovacs has announced that the first patient has been enrolled in the DOVACC (Durvalumab Olaparib VACCine) study, a randomized Phase II clinical trial assessing the impact of the Company’s telomerase vaccine, UV1, on the standard of maintenance care in ovarian cancer. DOVACC  is organized w
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.